Shao Yu Medical: It is expected that there will be 5-6 AI therapeutic robot series products gradually approved by 2026.

Xiangyu Medical discloses the investor relations activity record form, the company provides a complete set of solutions empowered by brain-machine interface, rather than single-point products. The company's related products have entered more than 600 Grade III hospitals, with a target of covering over 1,000 Grade III hospitals by 2026, accelerating the commercialization process and clinical landing. The company has formed a complete product matrix planning, with the AI rehabilitation robot series products covering massage robots, shock wave robots, upper limb multidimensional rehabilitation training robots, transcranial magnetic robots, moxibustion robots, electromagnetic therapy robots, radiofrequency therapy robots, etc., with 5-6 models expected to be successively certified by 2026; medical exoskeleton robots and portable exoskeleton robots are expected to be certified in the first half of 2026. Relying on mature rehabilitation equipment matrix and brain-machine interface technology for rapid upgrades, the core is to connect software and transform passive rehabilitation equipment into active rehabilitation equipment with deep brain involvement, with a relatively short upgrade cycle. By the end of June 2026, 27 core products are expected to complete multimodal and multi-paradigm upgrades; by the end of 2026, nearly 100 brain-machine interface products will be launched, with over 50 covering multimodal and multi-paradigm.